<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01263171</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000691166</org_study_id>
    <secondary_id>WCTU-COPERNICUS</secondary_id>
    <secondary_id>2010-023083-40</secondary_id>
    <secondary_id>C23134/A11537</secondary_id>
    <secondary_id>CARDIFF-SPON830-10</secondary_id>
    <nct_id>NCT01263171</nct_id>
  </id_info>
  <brief_title>Oxaliplatin, Leucovorin, and Fluorouracil Before and After Radiation Therapy and Surgery in Treating Patients With Rectal Cancer That Can Be Removed by Surgery</brief_title>
  <acronym>COPERNICUS</acronym>
  <official_title>A Stratified Phase II Study of Neoadjuvant Chemotherapy Given Before SCPRT as Treatment for Patients With MRI-Staged Operable Rectal Cancer at High Risk of Metastatic Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiff University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardiff University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells.&#xD;
      Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal&#xD;
      tissue that needs to be removed. Giving chemotherapy after surgery may kill any tumor cells&#xD;
      that remain after surgery.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying giving oxaliplatin, leucovorin, and fluorouracil&#xD;
      together, before and after radiation therapy and surgery in treating patients with rectal&#xD;
      cancer that can be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To assess the feasibility of introducing 8 weeks of neoadjuvant oxaliplatin and&#xD;
           fluorouracil followed by radiotherapy and immediate surgical resection in patients with&#xD;
           resectable adenocarcinoma of the rectum.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine feasibility of achieving dose intensity for chemotherapy and radiotherapy in&#xD;
           these patients.&#xD;
&#xD;
        -  Determine the safety, in terms of NCI CTCAE version 4 toxicities, including&#xD;
           postoperative complication rate (up to 30 days postoperatively), and late toxicity&#xD;
           assessment at 1 year following surgery, in these patients.&#xD;
&#xD;
        -  Determine how active is the neoadjuvant chemotherapy, in terms of down staging the&#xD;
           rectal cancer, local recurrence-free, distant metastasis-free, and overall survival at 1&#xD;
           year following surgery in these patients.&#xD;
&#xD;
      Neoadjuvant therapy: Patients receive oxaliplatin and leucovorin (L-leucovorin or leucovorin&#xD;
      calcium) IV over 2 hours on day 1 and fluorouracil IV over 46 hours on days 1-2. Treatment&#xD;
      repeats every 2 weeks for up to 4 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Radiotherapy/Surgery: Beginning 1 week after completion of chemotherapy, patients undergo&#xD;
      radiotherapy, followed by surgical resection of their primary tumor, within 7-14 days after&#xD;
      completion of radiotherapy. Between 6-8 weeks following surgery, patients begin adjuvant&#xD;
      therapy.&#xD;
&#xD;
      Adjuvant therapy: Patients receive oxaliplatin and leucovorin (L-leucovorin or leucovorin&#xD;
      calcium) IV over 2 hours on day 1 and fluorouracil IV over 46 hours on days 1-2. Treatment&#xD;
      repeats every 2 weeks for up to 8 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Blood and biopsy specimens are collected at baseline and periodically for translational&#xD;
      research studies.&#xD;
&#xD;
      After completion of study therapy, patients are followed up periodically for 1 year.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who commence neoadjuvant chemotherapy and radiotherapy and then undergo surgical resection</measure>
    <time_frame>Two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility in terms of achieved dose intensity for chemotherapy and radiotherapy</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety in terms of NCI CTCAE v 4 toxicities up to 30 days postoperatively and late toxicity at 1 year after surgery</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy in terms of down-staging rectal cancer</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local recurrence-free, distant metastasis-free, and overall survival at 1 year after surgery</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Neo-adjuvant chemotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Neo-adjuvant chemotherapy prior to short course pre-operative radiotherapy followed by adjuvant chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <arm_group_label>Neo-adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <arm_group_label>Neo-adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <arm_group_label>Neo-adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <arm_group_label>Neo-adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <arm_group_label>Neo-adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <arm_group_label>Neo-adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <arm_group_label>Neo-adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Neo-adjuvant chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histopathologically confirmed rectal adenocarcinoma meeting the following criteria:&#xD;
&#xD;
               -  Inferior aspect of tumor is &gt; 4 cm from anal verge on digital examination and&#xD;
                  pelvic MRI scan&#xD;
&#xD;
               -  Superior aspect of tumor is not higher than the anterior aspect of the S1/S2&#xD;
                  interspace on pelvic MRI scan&#xD;
&#xD;
               -  Mesorectal fascia is not threatened or involved (tumor &gt; 1 mm from mesorectal&#xD;
                  fascia)&#xD;
&#xD;
               -  Primary tumor meets 1 of the following criteria:&#xD;
&#xD;
                    -  T3a-b (mesorectal primary tumor invasion seen ≤ 5 mm beyond muscularis&#xD;
                       propria) in the presence of 1 of the following:&#xD;
&#xD;
                         -  Extra-mural vascular invasion&#xD;
&#xD;
                         -  Mesorectal lymph node(s)/tumor deposit(s) with irregular border and&#xD;
                            mixed signal intensity&#xD;
&#xD;
                    -  Any T3c (primary tumor invasion seen &gt; 5 mm beyond muscularis propria)-T4a&#xD;
                       (invasion of visceral peritoneum for tumors with a component above&#xD;
                       peritoneal reflection)&#xD;
&#xD;
               -  Low tumors should not involve levator ani (&gt; 1 mm gap between tumor and levator&#xD;
                  ani) or anal sphincters&#xD;
&#xD;
          -  No evidence of distant metastases or stage T4b cancer with invasion into adjacent&#xD;
             organs or structures&#xD;
&#xD;
          -  Must have measurable disease at the baseline visit&#xD;
&#xD;
          -  Impending rectal obstruction is permitted if relieved by a non-functioning ileostomy&#xD;
             or colostomy&#xD;
&#xD;
          -  No disease threatening mesorectal fascia (disease ≤ 1 mm from mesorectal fascia&#xD;
             whether this is primary tumor, extra-mural vascular invasion, or tumor deposit with&#xD;
             irregular border and mixed signal intensity)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  WBC ≥ 3 x 10^9/L&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1.5 x10^9/L&#xD;
&#xD;
          -  Platelet count ≥ 100 x10^9/L&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 5 x ULN&#xD;
&#xD;
          -  AST or ALT ≤ 2.5 x ULN&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Magnesium and calcium normal&#xD;
&#xD;
          -  Candidate for systemic therapy, in the opinion of the primary oncologist&#xD;
&#xD;
          -  No known significant impairment of intestinal absorption (e.g., chronic diarrhea,&#xD;
             inflammatory bowel disease)&#xD;
&#xD;
          -  No evidence of established or acute ischemic heart disease (e.g., left bundle branch&#xD;
             block, pathological q-waves, ST elevation, or ST-segment depression) and normal&#xD;
             clinical cardiovascular assessment by ECG&#xD;
&#xD;
          -  No enlarged pelvic sidewall lymph nodes&#xD;
&#xD;
          -  No severe local bowel symptoms of tenesmus or irregularity or frequency of bowel habit&#xD;
             precluding accurate assessment of diarrhea&#xD;
&#xD;
          -  No pelvic sepsis&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception during treatment and for 6 months&#xD;
             after completion of treatment&#xD;
&#xD;
          -  No other prior or current malignant disease that, in the judgement of the treating&#xD;
             investigator, is likely to interfere with study treatment or assessment of response&#xD;
&#xD;
          -  No clinically significant cardiovascular disease, including any of the following&#xD;
             within the past year:&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Serious uncontrolled cardiac arrhythmia&#xD;
&#xD;
          -  No history of interstitial lung disease (e.g., pneumonitis or pulmonary fibrosis or&#xD;
             evidence of interstitial lung disease)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior pelvic radiotherapy&#xD;
&#xD;
          -  No metallic colon stent or rectal stent in situ&#xD;
&#xD;
          -  More than 30 days since prior chemotherapy, radiotherapy, hormonal treatment, antibody&#xD;
             therapy, immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, matrix&#xD;
             metalloproteinase inhibitors, thalidomide, anti-VEGF/Flk-1 monoclonal antibodies, or&#xD;
             other experimental drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Gollins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glan Clwyd Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walsgrave Hospital</name>
      <address>
        <city>Coventry</city>
        <state>England</state>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rosemere Cancer Centre at Royal Preston Hospital</name>
      <address>
        <city>Preston</city>
        <state>England</state>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Center at Velindre Hospital</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glan Clwyd Hospital</name>
      <address>
        <city>Rhyl, Denbighshire</city>
        <state>Wales</state>
        <zip>LL 18 5UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>December 17, 2010</study_first_submitted>
  <study_first_submitted_qc>December 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2010</study_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>stage IIIB rectal cancer</keyword>
  <keyword>stage IIIC rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

